ArticleClinical journal of gastroenterology2026
A case of portal hypertension associated with a giant hepatic arterioportal fistula successfully treated with partial hepatic arterial embolization.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset symptomatic hepatic arterioportal fistula (HAPF) is a rare vascular abnormality for which optimal treatment strategies have not been established. We report a case of a symptomatic giant HAPF successfully treated with interventional radiology. A woman in her 60 s presented with massive ascites. Imaging studies revealed an intrahepatic HAPF with multiple abnormal communications between the posterior segmental branch of the portal vein and arterial inflow from the right hepatic artery and the right inferior phrenic artery, leading to a diagnosis of portal hypertension associated with HAPF. Due to the high surgical risk associated with massive ascites, partial transcatheter arterial embolization targeting the major hepatic arterial inflow was performed instead of using a portal venous approach. Although complete shunt occlusion was not achieved, the disappearance of early portal venous enhancement was used as the procedural endpoint, suggesting a marked reduction in hepatofugal portal flow. Following treatment, ascites resolved, serum albumin levels improved, and liver volume increased on follow-up imaging. The patient has remained recurrence-free for two years after treatment. Partial hepatic arterial embolization aimed at flow reduction, rather than complete shunt obliteration, may be an effective and less invasive therapeutic strategy for complex HAPF.
Indexed as
Identifiers
42474651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.